Frontline Aumolertinib Plus Anlotinib Elicits Responses in EGFR-Mutant NSCLC With Brain Metastases

2 years ago 61

Aumolertinib plus anlotinib resulted in intracranial efficacy when used in the first-line treatment of patients with EGFR-mutant non–small cell lung cancer who have brain metastases.

1. Homepage
2. Lung Cancer
3. Frontline Aumolertinib Plus Anlotinib Elicits Responses in EGFR-Mutant NSCLC With Brain Metastases